Marta Ribeiro,  —

Watch the video to learn a little bit more about Pulmonary Fibrosis, causes, symptoms and signs.   Learn more about PF here: http://bit.ly/1lfMsiZ…

  The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role…

Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was the first drug to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…

“Dolores has Idiopathic Pulmonary Fibrosis (IPF) and tells her story about living with lung disease. Dolores found help in dealing with her illness by contacting the Irish Lung Fibrosis Association (ILA).”   Learn more about IPF: http://bit.ly/1XjPFMa…

1. Esbriet’s Promise and Potential as a PF Therapy 2. IPF Experts Discuss Disease Diagnosis and Treatment at CHEST 2015 3. Boehringer Ingelheim’s OFEV (Nintedanib) IPF Therapy Reinforces Efficacy and Safety Profile in New Studies  …

Cotrimoxazole (Trisulfa-FPI) is a combination of trimethoprim and sulfamethoxazole in fixed amounts (trimethoprim 80 mg and sulfamethoxazole 400 mg) used to treat bacterial, fungal and protozoal infections. It is developed and marketed worldwide with different brand names including Septra (GlaxoSmithKline plc) and Bactrim (Hoffmann-La Roche). Being a broad…

“Patients, caregivers, and physicians discuss the disease and the role the Pulmonary Fibrosis Foundation has played in the past years.”   Learn more about Pulmonary Fibrosis Foundation: http://bit.ly/1MkiSzf  …

Evel Knievel was an American daredevil, entertainer, and international icon. He attempted more than 75 ramp-to-ramp motorcycle jumps between 1965 and 1980, and in 1974, a canyon jump across Snake River Canyon (which failed) in a team-powered rocket. During his career, he suffered more than 433 bone fractures, which gave…

Boehringer Ingelheim Pharmaceuticals recently presented results of the Phase III INPULSIS trials investigating the efficacy of OFEV ® (nintedanib) in patients with idiopathic pulmonary fibrosis (IPF) at the American College of Chest Physicians Annual Meeting (CHEST 2015). The Phase III INPULSIS trials were randomized, double-blind studies designed to assess both…

Learn more about Approved IPF Therapies Ofev and Esbriet. Read more about Pulmonary Fibrosis: http://bit.ly/1lfMsiZ…